eli lilly glp 1 market share GLP-1 boom makes the first $1 trillion pharma company Novo Nordisk grows GLP-1 market

Semaglutide GLP-1 is a peptide that functions by mimicking the action of a hormone known as glucagon-like peptide 1 (GLP-1)

It is essential to emphasise that patients with significant dyslipidaemia requiring substantial LDL cholesterol reduction should receive appropriate lipid-lowering therapy according to NICE guideline NG238

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the First-in-Class GLP-1 and Amylin Receptor Agonist, Amycretin: A First-in-Human, Phase 1, Double-Blind, Randomised, Placebo-Controlled Trial

Although CEO Albert Bourla believes recent acquisitions including most notably the 2023 Seagen purchase have brought in about $20bn in 2030 risk-adjusted revenues, the company is unlikely to report dazzling growth in 2025